Sutro Biopharma announces first patient dosed in Phase 1 trial of STRO-006
STRO•Sutro Biopharma said the first patient has been dosed in its Phase 1 trial of STRO-006, an ITGB6-targeting antibody-drug conjugate for advanced solid tumors. Initial clinical data are expected in the second half of 2027.
1. Phase 1 trial begins
The trial is evaluating STRO-006, a next-generation ITGB6-targeting antibody-drug conjugate, in patients with advanced solid tumors. Sutro Biopharma expects initial clinical data in the second half of 2027.
